These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29858025)

  • 1. Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival.
    Xie M; Wei S; Wu X; Li X; You Y; He C
    Lung Cancer; 2018 Jul; 121():41-47. PubMed ID: 29858025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
    Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
    J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Prognostic Significance of Notch1 and Fatty Acid Binding Protein 7 (FABP7) Expression in Resected Tracheobronchial Adenoid Cystic Carcinoma: A Multicenter Retrospective Study.
    Xie M; Wu X; Zhang J; He C; Wei S; Huang J; Fu X; Gu Y
    Cancer Res Treat; 2018 Oct; 50(4):1064-1073. PubMed ID: 29141398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem-Like Cells in Adenoid Cystic Carcinoma.
    Panaccione A; Chang MT; Carbone BE; Guo Y; Moskaluk CA; Virk RK; Chiriboga L; Prasad ML; Judson B; Mehra S; Yarbrough WG; Ivanov SV
    Clin Cancer Res; 2016 Apr; 22(8):2083-95. PubMed ID: 27084744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of Notch1 receptor and clinicopathological High-Risk Predictors in lacrimal gland adenoid cystic carcinoma.
    Anjum S; Sen S; Pushker N; Bajaj MS; Kashyap S; Bakhshi S; Chosdol K; Meel R; Sharma MC
    Acta Ophthalmol; 2021 Dec; 99(8):e1467-e1473. PubMed ID: 33675181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.
    Stoeck A; Lejnine S; Truong A; Pan L; Wang H; Zang C; Yuan J; Ware C; MacLean J; Garrett-Engele PW; Kluk M; Laskey J; Haines BB; Moskaluk C; Zawel L; Fawell S; Gilliland G; Zhang T; Kremer BE; Knoechel B; Bernstein BE; Pear WS; Liu XS; Aster JC; Sathyanarayanan S
    Cancer Discov; 2014 Oct; 4(10):1154-67. PubMed ID: 25104330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma.
    Sajed DP; Faquin WC; Carey C; Severson EA; H Afrogheh A; A Johnson C; Blacklow SC; Chau NG; Lin DT; Krane JF; Jo VY; Garcia JJ; Sholl LM; Aster JC
    Am J Surg Pathol; 2017 Nov; 41(11):1473-1482. PubMed ID: 28914715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole Exome Sequencing of Lacrimal Gland Adenoid Cystic Carcinoma.
    Sant DW; Tao W; Field MG; Pelaez D; Jin K; Capobianco A; Dubovy SR; Tse DT; Wang G
    Invest Ophthalmol Vis Sci; 2017 May; 58(6):BIO240-BIO246. PubMed ID: 28820917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NOTCH1-HEY1 pathway regulates self-renewal and epithelial-mesenchymal transition of salivary adenoid cystic carcinoma cells.
    Xie J; Lin LS; Huang XY; Gan RH; Ding LC; Su BH; Zhao Y; Lu YG; Zheng DL
    Int J Biol Sci; 2020; 16(4):598-610. PubMed ID: 32025208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
    Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
    Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
    Ferrarotto R; Eckhardt G; Patnaik A; LoRusso P; Faoro L; Heymach JV; Kapoun AM; Xu L; Munster P
    Ann Oncol; 2018 Jul; 29(7):1561-1568. PubMed ID: 29726923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
    Even C; Lassen U; Merchan J; Le Tourneau C; Soria JC; Ferte C; Ricci F; Diener JT; Yuen E; Smith C; Oakley GJ; Benhadji KA; Massard C
    Invest New Drugs; 2020 Apr; 38(2):402-409. PubMed ID: 30953269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Notch activation promotes bone metastasis via SPARC inhibition in adenoid cystic carcinoma.
    Zhang Y; Liu X; Zhu L; Zhou Z; Cui Y; Zhou CX; Li TJ
    Oral Dis; 2024 Apr; 30(3):1220-1233. PubMed ID: 36951790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oncogenic effects of HES1 on salivary adenoid cystic carcinoma cell growth and metastasis.
    Huang XY; Gan RH; Xie J; She L; Zhao Y; Ding LC; Su BH; Zheng DL; Lu YG
    BMC Cancer; 2018 Apr; 18(1):436. PubMed ID: 29665790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival after resection of primary adenoid cystic and squamous cell carcinoma of the trachea and carina.
    Gaissert HA; Grillo HC; Shadmehr MB; Wright CD; Gokhale M; Wain JC; Mathisen DJ
    Ann Thorac Surg; 2004 Dec; 78(6):1889-96; discussion 1896-7. PubMed ID: 15560996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma with and without NOTCH signaling pathway activation.
    Feeney L; Hapuarachi B; Adderley H; Rack S; Morgan D; Walker R; Rauch R; Herz E; Kaye J; Harrington K; Metcalf R
    Oral Oncol; 2022 Oct; 133():106028. PubMed ID: 35952580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.
    Hanna GJ; Grover P; Elliott A; McGrath J; Xiu J; Sukari A; Johnson JM; Wise-Draper T
    Clin Cancer Res; 2024 May; 30(10):2225-2232. PubMed ID: 38416410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HEY1 is expressed independent of NOTCH1 and is associated with poor prognosis in head and neck squamous cell carcinoma.
    Rettig EM; Bishop JA; Agrawal N; Chung CH; Sharma R; Zamuner F; Li RJ; Koch WM; Califano JA; Guo T; Gaykalova DA; Fakhry C
    Oral Oncol; 2018 Jul; 82():168-175. PubMed ID: 29909892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
    Wang K; Zhang Q; Li D; Ching K; Zhang C; Zheng X; Ozeck M; Shi S; Li X; Wang H; Rejto P; Christensen J; Olson P
    Clin Cancer Res; 2015 Mar; 21(6):1487-96. PubMed ID: 25564152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-NOTCH1 therapy with OMP-52 M51 inhibits salivary adenoid cystic carcinoma by depressing epithelial-mesenchymal transition (EMT) process and inducing ferroptosis.
    Li R; Hu Z; Qiao Q; Zhou D; Sun M
    Toxicol Appl Pharmacol; 2024 Mar; 484():116825. PubMed ID: 38253083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.